Aclaris Therapeutics Inc. (ACRS) Sees Large Volume Increase
Aclaris Therapeutics Inc. (NASDAQ:ACRS) shares saw an uptick in trading volume on Wednesday . 134,342 shares traded hands during trading, an increase of 24% from the previous session’s volume of 108,375 shares.The stock last traded at $24.57 and had previously closed at $24.38.
Several brokerages have issued reports on ACRS. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th. Guggenheim started coverage on Aclaris Therapeutics in a report on Friday, June 10th. They set a “buy” rating and a $35.00 target price for the company. Finally, Jefferies Group lifted their target price on Aclaris Therapeutics from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, August 12th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $31.25.
The stock’s market capitalization is $524.67 million. The firm has a 50 day moving average price of $21.21 and a 200-day moving average price of $19.73.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/aclaris-therapeutics-inc-acrs-sees-large-volume-increase.html
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.01. On average, analysts forecast that Aclaris Therapeutics Inc. will post ($2.61) EPS for the current fiscal year.
In related news, insider Kamil Ali-Jackson sold 3,738 shares of the company’s stock in a transaction on Friday, August 26th. The stock was sold at an average price of $20.35, for a total transaction of $76,068.30. Following the completion of the sale, the insider now owns 20,289 shares in the company, valued at $412,881.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of the company’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $24.19, for a total value of $12,713,054.50. The disclosure for this sale can be found here. Corporate insiders own 46.40% of the company’s stock.
Large investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new stake in shares of Aclaris Therapeutics during the first quarter valued at about $79,427,000. Opaleye Management Inc. bought a new stake in shares of Aclaris Therapeutics during the first quarter valued at about $341,000. EAM Investors LLC bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $668,000. BlackRock Institutional Trust Company N.A. increased its stake in shares of Aclaris Therapeutics by 24.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 28,286 shares of the company’s stock valued at $536,000 after buying an additional 5,535 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Aclaris Therapeutics by 18.3% in the first quarter. Geode Capital Management LLC now owns 43,246 shares of the company’s stock valued at $819,000 after buying an additional 6,679 shares during the period. Institutional investors and hedge funds own 71.39% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.